razaxaban has been researched along with rivaroxaban in 2 studies
| Studies (razaxaban) | Trials (razaxaban) | Recent Studies (post-2010) (razaxaban) | Studies (rivaroxaban) | Trials (rivaroxaban) | Recent Studies (post-2010) (rivaroxaban) |
|---|---|---|---|---|---|
| 20 | 0 | 2 | 4,741 | 569 | 4,357 |
| Protein | Taxonomy | razaxaban (IC50) | rivaroxaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.0038 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheney, DL; Knabb, RM; Pinto, DJ; Smallheer, JM; Wexler, RR | 1 |
| Barrett, YC; Frost, C; Shenker, A; Wang, Z | 1 |
1 review(s) available for razaxaban and rivaroxaban
| Article | Year |
|---|---|
Factor Xa inhibitors: next-generation antithrombotic agents.
Topics: Administration, Oral; Animals; Anticoagulants; Biological Availability; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Hemostasis; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Thrombosis | 2010 |
1 other study(ies) available for razaxaban and rivaroxaban
| Article | Year |
|---|---|
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Humans; International Normalized Ratio; Isoxazoles; Morpholines; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |